In line with this hypothesis, we demonstrated that CLL cells treated with defactinib have significantly reduced migratory and invasive potential, indicating that FAK inhibition could effectively reduce CLL lymph node ingress. The gene discussed is PTK2; the disease is B-cell chronic lymphocytic leukemia.